SUNZEN 0148 Share Price
RM0.23
klse: Sunzen Group Berhad
Stock Information
Board : Ace
Shariah : Non-Shariah Compliant
Sector : Animal Health Products Pharmaceuticals Healthcare Products
Address: 1, Jalan Anggerik Mokara 31/47, Kawasan Industri Kota Kemuning, 40460 Shah Alam, Selangor
Contact: +603-51229333
Website: https://www.sunzen.com.my/
Stock Background
Sunzen Group Berhad operates through manufacturing divisions and trading division. The Manufacturing division is involved in the manufacturing and marketing of animal health products such as orgacids, zenacids, om, pfactor, and pfi-lyte. In addition, it also produces palm oil products such as powder fats for livestock animals. The Trading division includes the distribution and marketing of veterinary pharmaceuticals and animal vaccines, and detergent and disinfectant products
Profit Analysis: SUNZEN 0148
|
Result
Quarter Report History
| Date | Revenue,k | PBT,k | Net Profit,k |
|---|---|---|---|
| 25/05/26 | 23,973 | 3,147 | 2,138 |
| 27/02/26 | 30,241 | 6,648 | 4,835 |
| 26/11/25 | 19,676 | 3,689 | 2,709 |
| 29/08/25 | 14,982 | -528 | -817 |
| 27/05/25 | 15,687 | 1,924 | 1,187 |
| 25/02/25 | 27,346 | 2,893 | 1,942 |
| 22/11/24 | 22,964 | 860 | 482 |
| 29/08/24 | 20,611 | 841 | 403 |
| 24/05/24 | 23,958 | 3,080 | 1,971 |
| 29/02/24 | 29,338 | 4,843 | 3,110 |
| 29/11/23 | 25,982 | 3,178 | 1,693 |
| 30/08/23 | 19,775 | 1,708 | 921 |
Fundamental
Fundamental Analysis
| Last 4 Quarter Revenue (RM’000) | 89 |
|---|---|
| Last 4 Quarter Net Profit (RM’000) | 9,157 |
| Last 4 Quarter EPS (sen) | 1.15 |
| Last 4 Quarter PER | 20.13 |
| Last 4 Quarter Dividend (sen) | 20.00 |
| Last 4 Quarter Dividend Yield (%) | 0.87 |
| Net Tangible Assets (RM) | 1900.00 |
| Goodwill (RM) | 6,230 |
| Cash (RM’000) | 25,940 |
| Debt (RM’000) | 21,950 |
| Total Debt (RM’000) | 40,520 |
| Net Assets (RM’000) | 153,150 |
| Current Ratio | 6.06 |
| Quick Ratio | 5.10 |
| Cash Ratio | 1.77 |
Technical
Technical Analysis
| MACD (26 vs 12) | -4.498 |
|---|---|
| Exponential Moving Average 5 | 0.232 |
| Exponential Moving Average 20 | 0.23 |
| Exponential Moving Average 90 | 0.244 |
| Relative Strength Index 14 | 0.50 |
| Stochastic %D 3 | 0.67 |
| Stochastic %K 14 | 0.67 |
11 reviews for SUNZEN 0148
Only logged in customers who have purchased this product may leave a review.
-
BNASTRA 7195 ★★★★★RM2.14 - PETRONM 3042 ★★★★★RM3.44
- CMSB 2852 ★★★★★RM1.00
- SUNREIT 5176 ★★★★★RM2.23
Salary Proof
BURSA MALAYSIA –
The Group registered a lower pre-tax profit of approximately RM1.64 million in the current quarter compared to RM1.71 million in the preceding quarter, mainly due to lower profit contribution on lower export sales of edible bird’s nest, higher marketing and distribution expenses incurred and lower reversal of impairment loss on receivables in the current quarter.
BURSA MALAYSIA –
The Group registered a lower pre-tax profit of RM1.71 million for the current quarter compared to RM1.84 million in the preceding quarter, mainly due to lower profit contribution on lower sales recorded from TCM segment. Net profit attributable to equity holders of the Company is RM0.95 million for the current quarter compared to RM0.80 million for the preceding quarter.
BURSA MALAYSIA –
The Group registered a lower pre-tax profit of RM1.84 million for the current quarter compared to pre-tax profit of RM2.16 million in the preceding quarter, mainly due to lower margin from TCM segment and the recognition of employee benefit (non-cash) of RM0.45 million in respect of Share Issuance Scheme, despite the fact that loan financing contributed higher earnings in the current quarter
BURSA MALAYSIA –
Group’s pre-tax profit posted approximately a 3.10% increase to RM2.16 million in the current quarter from RM2.09 million in the preceding quarter despite a lower earnings contribution from TCM segment for the current quarter amid a lower revenue, mainly attributed to higher earnings contribution from money lending business coupled with a lower loss incurred by animal health business in the current quarter.
BURSA MALAYSIA –
Group’s pre-tax profit posted a 29.54% quarter-on-quarter decrease to RM0.52 million from RM0.74 million in the preceding quarter, mainly attributed to the preceding quarter included a one-off gain on disposal of property as other income
BURSA MALAYSIA –
The Group reported a pre-tax profit of RM0.38 million over a revenue of RM23.65 million in the current quarter compared to a pre-tax loss of RM7.83 million and a revenue of RM27.86 million in the preceding quarter, in which the recognition of fair value of share option granted which amounted to RM9.42 million was included.
The Star –
Sunzen Biotech Bhd’s shares rose over 8% in early trade Thursday following its plan to diversify into money-lending business. Sunzen aims to diversify into the money-lending business with the proposed acquisition of the entire equity stake in Finsource Solution Sdn Bhd via a conditional share sale agreement for RM6.8mil. Sunzen said the acquisition will be satisfied by the allotment and issuance of 41.21 million new ordinary shares in the group at an issue price of 16.5 sen.
BURSA MALAYSIA –
Loss before tax for the current quarter reported 42.75% lower compared to the preceding quarter. Current quarter under review reported a lower loss before tax in spite of having lower revenue, mainly attributed to the improved profit contribution coupled with lower operating expenses for Traditional Chinese medicines segment.
REMUNERATION STUDY –
In Financial Year End 2019, the directors’ remuneration was 0.76 million. It was slightly low compared to average in listed companies, considering the employees’ remuneration of 11.9 million and auditor’s remuneration of 139 thousands
BURSA MALAYSIA –
The Group reported a 51.83% decrease in revenue compared to preceding quarter mainly due to the decrease in trading volume of CPO and lower sales of foods and beverages (“TCM”) in the current quarter.
INVESTING MALAYSIA –
SUNZEN (6 JAN 20) Bursa Malaysia Securities Berhad (BMSB) has publicly reprimanded Sunzen Biotech Bhd and two of its executive directors for failing to obtain prior shareholders’ approval in respect of its diversification into a new business in the trading of crude palm oil (CPO) and its derivative products such as palm kernel and palm kernel shell in February 2017.
Investing Malaysia –
Average investing volume for Sunzen Biotech Bhd in the past three months in stock market was 143.6k lots
Investing Malaysia –
SUNZEN gets a score of 19.11 in our equity and assets quality test based on current share price of RM0.115
Investing Malaysia –
Sunzen Biotech Bhd gets a score of 18.25 in our stability test after the balance sheet, money statement study
Investing Malaysia –
Stock code of 0148 in Bursa Malaysia declared adjusted 0.22% dividend yield in past few years
Investing Malaysia –
SUNZEN is forecasted to made loss of 3.57 millions, with an adjusted market capitalization of 60.81 millions
REMUNERATION STUDY –
In Financial Year End 2018, the directors’ remuneration was 0.68 million. It was slightly low compared to average in listed companies, considering the employees’ remuneration of 9.7 million and auditor’s remuneration of 128 thousands